Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$24.03 - $27.02 $36,045 - $40,530
-1,500 Reduced 3.34%
43,400 $321,000
Q3 2022

Nov 14, 2022

BUY
$11.6 - $20.44 $184,440 - $324,996
15,900 Added 54.83%
44,900 $120,000
Q2 2022

Aug 12, 2022

BUY
$7.78 - $14.69 $35,010 - $66,105
4,500 Added 18.37%
29,000 $42,000
Q1 2022

May 12, 2022

BUY
$11.38 - $16.4 $278,810 - $401,799
24,500 New
24,500 $59,000
Q2 2021

Aug 11, 2021

SELL
$17.07 - $24.56 $209,961 - $302,088
-12,300 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$20.46 - $25.18 $8,184 - $10,072
-400 Reduced 3.15%
12,300 $16,000
Q3 2020

Nov 13, 2020

BUY
$14.05 - $22.6 $25,290 - $40,680
1,800 Added 16.51%
12,700 $5,000
Q2 2020

Aug 10, 2020

BUY
$7.34 - $20.84 $80,006 - $227,156
10,900 New
10,900 $47,000

Others Institutions Holding MYOV

About Myovant Sciences Ltd.


  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.